BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 17071050)

  • 1. Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
    Huang PW; Gu YH; Lu KH; Shu YQ
    Biomed Pharmacother; 2006 Dec; 60(10):698-700. PubMed ID: 17071050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
    Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
    Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
    Rowinsky EK; Flood WA; Sartorius SE; Bowling MK; Wagner J; Ettinger DS
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):48-54. PubMed ID: 7644928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study.
    Ratanatharathorn V; Jirajarus M; Sirachainan E; Sirilerttrakul S; Euaree A; Supatchaipisit P
    J Med Assoc Thai; 1998 Oct; 81(10):763-71. PubMed ID: 9803067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
    Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
    Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y
    Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
    Hashizume T; Ogura T; Kozawa S; Yamaguchi N; Hayashi M; Nakamura M; Miyazawa N; Watanuki Y; Takahashi H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):471-5. PubMed ID: 16612156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
    McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
    Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Imai H; Utsugi M; Shimizu Y; Iijima H; Tomizawa Y; Hisada T; Ishizuka T; Saito R; Mori M
    Anticancer Drugs; 2007 Apr; 18(4):471-6. PubMed ID: 17351400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
    Nakadate M; Yamazaki K; Konishi J; Kinoshita I; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
    Anticancer Res; 2006; 26(5B):3767-72. PubMed ID: 17094399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
    Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
    Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.